Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-08-08

Clinical Trial Update: Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating valsartan for suppression of plaque volume and restenosis after a drug-eluting stent in coronary artery disease has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VALSARTAN (Valsartan)

Snippet

Sponsor: Seung-Jung Park | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED